About Eisbach Bio

Eisbach develops novel drugs that disrupt molecular machines essential to tumors with defined genetic vulnerabilities in the context of DNA damage and repair (DDR). Its proprietary platform creates targeted therapies that exploit disease-relevant vulnerabilities. By shutting off the machine’s engine using allosteric inhibitors, Eisbach’s medicines are designed to prevent the reorganization and evolution of cancer genomes. Founded in 2019, Eisbach is privately held and backed by international investors.

Facts about Eisbach Bio
  • Founding: 2019
  • Focus : Manufacturer
  • Employees: 1-10
  • Industry : Biotechnology, Pharma

Product portfolio of Eisbach Bio

Product portfolio

Here you will find Eisbach Bio GmbH